trial

Bromocriptine for Patients With Schizophrenia and Prediabetes

NCTId NCT03575000
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 15 (estimated)
Sponsored by VA Pittsburgh Healthcare System
Primary completion 2026-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
15 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-01-01
Primary completion
2026-07-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Bromocriptine

Sponsors

VA Pittsburgh Healthcare SystemLead Sponsor

Investigators

1
Ronald Codario, M.D.Principal Investigator

Sites

1 total
Pittsburgh, United States

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE4
Primary Completion Date
2026-07-31
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Bromocriptine
drug
lead_sponsor
VA Pittsburgh Healthcare System
company
indication
Prediabetic State
indication
Schizophrenia
indication
PreDiabetes
indication
investigator
Ronald Codario, M.D.
person